drugset / Trial / NCT05638334
Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the whole-body biodistribution and tumour uptake of 89Zr-S095012 in participants with solid tumours treated with S095012 (PD-L1x4-1BB bispecific antibody)
Timeline
- Start
- 2022-11-21
- Primary completion
- 2024-06-14
- Completion
- 2024-06-14
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 89Zr-S095012 | Diagnostic / imaging agent | — | Intravenous |
| Subject | S095012 | Monoclonal antibody | — | Intravenous |